Opinion / Emma Searle
Continental shift
The G7’s commitment to Africa has dwindled over the past 20 years. Foreign aid and debt relief, once prominent features at G7 gatherings of the late 1990s, have since taken a back seat. At this weekend’s summit in Cornwall, Africa will be represented by South Africa’s president Cyril Ramaphosa (pictured, on right, with Emmanuel Macron), who will see this as a crucial opportunity to get the priorities of his country and the continent back on the agenda.
Ramaphosa intends to bring a message of hope and recovery to the summit, signalling that his country is emerging from the pandemic. But his central pitch will be to let Africa help itself by producing more vaccines rather than waiting on handouts from abroad. Together with India’s Narendra Modi, who will be joining remotely, Ramaphosa hopes to persuade G7 nations to agree to a temporary waiver on some intellectual property rights for inoculations, which in turn could pave the way for an African-made jab. “If the international community is truly committed to human rights, vaccines should be viewed as a global public good,” Ramaphosa said in a statement last month.
Africa currently accounts for less than 5 per cent of the world’s vaccine-manufacturing capacity. Public-health experts believe that a locally-made coronavirus vaccine – even one based on the science of a formula developed in the West – could go a long way to boosting public confidence. “Africans are becoming less trusting of vaccines imported from the West because they don’t want to be treated as guinea pigs," Christian Happi, a Cameroonian infectious-disease specialist, whose own coronavirus vaccine is in stage-2 trials, recently told Monocle 24. “If a vaccine were to be developed in Africa, we’d see a different response on the continent because they will identify with that vaccine.” As leaders prepare to meet for this week’s G7 summit, let’s hope that Africa is more than a mere footnote to proceedings.